IP Library › Granted Patent US 12,247,070
Granted Patent B2
US 12,247,070 · App. 17/418,681 · Granted Mar 11, 2025

Use of anti-FAM19A5 antibodies for treating atherosclerosis

Inventors: Bongcheol Kim (Seongnam-si, KR); Dong Sik Kim (Seoul, KR); Jae-Keun Lee (Seoul, KR); Juwon Shim (Seoul, KR)
Assignee: NEURACLE SCIENCE CO., LTD.
C07K16/24A61P9/10A61K2039/505C07K2317/24C07K2317/33C07K2317/52C07K2317/565C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,247,070
App. No.
17/418,681
Granted
Mar 11, 2025
Kind
B2
Abstract

The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat an atherosclerosis in a subject in need thereof.

Claims (195)

1. A method of increasing a migration and/or accumulation of macrophages at an atherosclerotic lesion site in a subject in need thereof comprising administering to the subject an antagonist against a family with sequence similarity 19, member A5 (“FAM19A5”) protein (“FAM19A5 antagonist”),

wherein the FAM19A5 antagonist comprises an antibody, or an antigen-binding portion thereof, that specifically binds to the FAM19A5 protein (“anti-FAM19A5 antibody”), a polynucleotide encoding the anti-FAM19A5 antibody, a vector comprising the polynucleotide, or a combination thereof,

wherein the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3, wherein:

(i) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 89, SEQ ID NO: 95, SEQ ID NO: 101, SEQ ID NO: 107, SEQ ID NO: 113, SEQ ID NO: 119, SEQ ID NO: 125, SEQ ID NO: 131, SEQ ID NO: 137, SEQ ID NO: 143, SEQ ID NO: 149, SEQ ID NO: 218, SEQ ID NO: 220, SEQ ID NO: 222, or SEQ ID NO: 223;

(ii) the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 90, SEQ ID NO: 96, SEQ ID NO: 102, SEQ ID NO: 108, SEQ ID NO: 114, SEQ ID NO: 120, SEQ ID NO: 126, SEQ ID NO: 132, SEQ ID NO: 138, SEQ ID NO: 144, SEQ ID NO: 150, SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 252, or SEQ ID NO: 253;

(iii) the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22, SEQ ID NO: 91, SEQ ID NO: 97, SEQ ID NO: 103, SEQ ID NO: 109, SEQ ID NO: 115, SEQ ID NO: 121, SEQ ID NO: 127, SEQ ID NO: 133, SEQ ID NO: 139, SEQ ID NO: 145, SEQ ID NO: 151, SEQ ID NO: 246, or SEQ ID NO: 247;

(iv) the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 92, SEQ ID NO: 98, SEQ ID NO: 104, SEQ ID NO: 110, SEQ ID NO: 116, SEQ ID NO: 122, SEQ ID NO: 134, SEQ ID NO: 140, SEQ ID NO: 146, SEQ ID NO: 152, SEQ ID NO: 208, SEQ ID NO: 225, or SEQ ID NO: 248;

(v) the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 33, SEQ ID NO: 93, SEQ ID NO: 99, SEQ ID NO: 105, SEQ ID NO: 111, SEQ ID NO: 117, SEQ ID NO: 123, SEQ ID NO: 129, SEQ ID NO: 135, SEQ ID NO: 141, SEQ ID NO: 147, SEQ ID NO: 153, SEQ ID NO: 209, SEQ ID NO: 213, SEQ ID NO: 224, SEQ ID NO: 226, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, or SEQ ID NO: 232; and

(vi) the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 31, SEQ ID NO: 34, SEQ ID NO: 94, SEQ ID NO: 100, SEQ ID NO: 106, SEQ ID NO: 112, SEQ ID NO: 118, SEQ ID NO: 124, SEQ ID NO: 130, SEQ ID NO: 136, SEQ ID NO: 142, SEQ ID NO: 148, SEQ ID NO: 154, SEQ ID NO: 227, SEQ ID NO: 231, or SEQ ID NO: 233.

2. The method of claim 1 , wherein the increased migration and/or accumulation of macrophages at an atherosclerotic lesion site is associated with a decrease in a low density lipoprotein (LDL) level of the subject.

3. A method of reducing a low density lipoprotein (LDL) level in a subject in need thereof comprising administering to the subject an antagonist against a family with sequence similarity 19, member A5 (“FAM19A5”) protein (“FAM19A5 antagonist”),

wherein the FAM19A5 antagonist comprises an antibody, or an antigen-binding portion thereof, that specifically binds to the FAM19A5 protein (“anti-FAM19A5 antibody”), a polynucleotide encoding the anti-FAM19A5 antibody, a vector comprising the polynucleotide, or a combination thereof,

wherein the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3, wherein:

(i) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 89, SEQ ID NO: 95, SEQ ID NO: 101, SEQ ID NO: 107, SEQ ID NO: 113, SEQ ID NO: 119, SEQ ID NO: 125, SEQ ID NO: 131, SEQ ID NO: 137, SEQ ID NO: 143, SEQ ID NO: 149, SEQ ID NO: 218, SEQ ID NO: 220, SEQ ID NO: 222, or SEQ ID NO: 223;

(ii) the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 90, SEQ ID NO: 96, SEQ ID NO: 102, SEQ ID NO: 108, SEQ ID NO: 114, SEQ ID NO: 120, SEQ ID NO: 126, SEQ ID NO: 132, SEQ ID NO: 138, SEQ ID NO: 144, SEQ ID NO: 150, SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 252, or SEQ ID NO: 253;

(iii) the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22, SEQ ID NO: 91, SEQ ID NO: 97, SEQ ID NO: 103, SEQ ID NO: 109, SEQ ID NO: 115, SEQ ID NO: 121, SEQ ID NO: 127, SEQ ID NO: 133, SEQ ID NO: 139, SEQ ID NO: 145, SEQ ID NO: 151, SEQ ID NO: 246, or SEQ ID NO: 247;

(iv) the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 92, SEQ ID NO: 98, SEQ ID NO: 104, SEQ ID NO: 110, SEQ ID NO: 116, SEQ ID NO: 122, SEQ ID NO: 134, SEQ ID NO: 140, SEQ ID NO: 146, SEQ ID NO: 152, SEQ ID NO: 208, SEQ ID NO: 225, or SEQ ID NO: 248;

(v) the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 33, SEQ ID NO: 93, SEQ ID NO: 99, SEQ ID NO: 105, SEQ ID NO: 111, SEQ ID NO: 117, SEQ ID NO: 123, SEQ ID NO: 129, SEQ ID NO: 135, SEQ ID NO: 141, SEQ ID NO: 147, SEQ ID NO: 153, SEQ ID NO: 209, SEQ ID NO: 213, SEQ ID NO: 224, SEQ ID NO: 226, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, or SEQ ID NO: 232; and

(vi) the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 31, SEQ ID NO: 34, SEQ ID NO: 94, SEQ ID NO: 100, SEQ ID NO: 106, SEQ ID NO: 112, SEQ ID NO: 118, SEQ ID NO: 124, SEQ ID NO: 130, SEQ ID NO: 136, SEQ ID NO: 142, SEQ ID NO: 148, SEQ ID NO: 154, SEQ ID NO: 227, SEQ ID NO: 231, or SEQ ID NO: 233.

4. A method of treating an atherosclerosis in a subject in need thereof comprising administering to the subject an antagonist against a family with sequence similarity 19, member A5 (“FAM19A5”) protein (“FAM19A5 antagonist”),

wherein the FAM19A5 antagonist comprises an antibody, or an antigen-binding portion thereof, that specifically binds to the FAM19A5 protein (“anti-FAM19A5 antibody”), a polynucleotide encoding the anti-FAM19A5 antibody, a vector comprising the polynucleotide, or a combination thereof,

wherein the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3, wherein:

(i) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 89, SEQ ID NO: 95, SEQ ID NO: 101, SEQ ID NO: 107, SEQ ID NO: 113, SEQ ID NO: 119, SEQ ID NO: 125, SEQ ID NO: 131, SEQ ID NO: 137, SEQ ID NO: 143, SEQ ID NO: 149, SEQ ID NO: 218, SEQ ID NO: 220, SEQ ID NO: 222, or SEQ ID NO: 223;

(ii) the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 90, SEQ ID NO: 96, SEQ ID NO: 102, SEQ ID NO: 108, SEQ ID NO: 114, SEQ ID NO: 120, SEQ ID NO: 126, SEQ ID NO: 132, SEQ ID NO: 138, SEQ ID NO: 144, SEQ ID NO: 150, SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 252, or SEQ ID NO: 253;

(iii) the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22, SEQ ID NO: 91, SEQ ID NO: 97, SEQ ID NO: 103, SEQ ID NO: 109, SEQ ID NO: 115, SEQ ID NO: 121, SEQ ID NO: 127, SEQ ID NO: 133, SEQ ID NO: 139, SEQ ID NO: 145, SEQ ID NO: 151, SEQ ID NO: 246, or SEQ ID NO: 247;

(iv) the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 92, SEQ ID NO: 98, SEQ ID NO: 104, SEQ ID NO: 110, SEQ ID NO: 116, SEQ ID NO: 122, SEQ ID NO: 134, SEQ ID NO: 140, SEQ ID NO: 146, SEQ ID NO: 152, SEQ ID NO: 208, SEQ ID NO: 225, or SEQ ID NO: 248;

(v) the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 33, SEQ ID NO: 93, SEQ ID NO: 99, SEQ ID NO: 105, SEQ ID NO: 111, SEQ ID NO: 117, SEQ ID NO: 123, SEQ ID NO: 129, SEQ ID NO: 135, SEQ ID NO: 141, SEQ ID NO: 147, SEQ ID NO: 153, SEQ ID NO: 209, SEQ ID NO: 213, SEQ ID NO: 224, SEQ ID NO: 226, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, or SEQ ID NO: 232; and

(vi) the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 31, SEQ ID NO: 34, SEQ ID NO: 94, SEQ ID NO: 100, SEQ ID NO: 106, SEQ ID NO: 112, SEQ ID NO: 118, SEQ ID NO: 124, SEQ ID NO: 130, SEQ ID NO: 136, SEQ ID NO: 142, SEQ ID NO: 148, SEQ ID NO: 154, SEQ ID NO: 227, SEQ ID NO: 231, or SEQ ID NO: 233.

5. The method of claim 4 , wherein the atherosclerosis is associated with: (i) a disease comprising a coronary heart disease (CHD), carotid artery disease, peripheral artery disease, chronic kidney disease, stroke, retinal artery occlusion, abdominal pain caused by intestinal damage, peritonitis, or combinations thereof; (ii) a high fat and/or high cholesterol (hypercholesterolemic) diet; (iii) an increased total cholesterol level, increased triglyceride level, increased LDL level, decreased HDL level, increased number and/or retention of oxo-LDL-induced foam cells within a plaque, or combinations thereof, compared to a subject without atherosclerosis; or (iv) a combination thereof.

6. The method of claim 4 , wherein after the administration, the subject exhibits a decreased low density lipoprotein (LDL) level.

7. The method of claim 6 , wherein after the administration, the subject exhibits: (i) an increased migration and/or accumulation of macrophages at an atherosclerotic lesion site of a blood vessel; (ii) an increased phagocytosis of LDL by macrophages at an atherosclerotic lesion site of a blood vessel; or (iii) both (i) and (ii).

8. The method of claim 7 , wherein the blood vessel comprises an artery, vein, capillary, or combinations thereof.

9. The method of claim 8 , wherein the artery is an aorta.

10. The method of claim 4 , wherein the anti-FAM19A5 antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein:

(i) the VH comprises the amino acid sequence set forth in SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEO ID NO: 158, SEO ID NO: 159, SEO ID NO: 160, SEO ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 211, SEQ ID NO: 214, SEQ ID NO: 249, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 250, or SEO ID NO: 251; and

(ii) the VL comprises the amino acid sequence set forth in SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 212, SEQ ID NO: 215, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, or SEQ ID NO: 245.

11. The method of claim 4 , wherein the anti-FAM19A5 antibody comprises a Fab, Fab′, F(ab′)2, Fv, or single chain Fv (scFv).

12. The method of claim 4 , wherein the anti-FAM19A5 antibody is a chimeric antibody, or a humanized antibody.

13. The method of claim 4 , wherein the FAM19A5 antagonist is: (i) linked to a molecule having a second binding moiety, thereby forming a bispecific molecule; (ii) linked to an agent, thereby forming an immunoconjugate, or (iii) both (i) and (ii).

14. The method of claim 1 , wherein:

(a) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 11, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 23, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25;

(b) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 15, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 27, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 28;

(c) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 18, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 29, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 30, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 31;

(d) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 20, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 21, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 22, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 32, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 33, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 34;

(e) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 89, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 90, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 91, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 92, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 93, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 94;

(f) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 95, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 96, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 97, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 98, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 99, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 100;

(g) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 101, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 102, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 103, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 104, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 105, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 106;

(h) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 107, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 108, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 109, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 110, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 111, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 112;

(i) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 113, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 114, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 115, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 116, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 117, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 118;

(j) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 119, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 120, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 121, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 122, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 123, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 124;

(k) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 125, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 126, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 127, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 128, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 129, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 130;

(l) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 131, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 132, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 133, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 134, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 135, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 136;

(m) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 137, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 138, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 139, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 140, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 141, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 142;

(n) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 143, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 144, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 145, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 146, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 147, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 148;

(o) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 149, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 150, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 151, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 152, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 153, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 154;

(p) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 18, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 208, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 209, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 31;

(q) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 252, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 208, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 213, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 31;

(r) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 253, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 208, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 213, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 31;

(s) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 218, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 219, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 224, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 28;

(t) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 225, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 226, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 227;

(u) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 225, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 228, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 227;

(v) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 229, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 227;

(w) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 228, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 227;

(x) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 230, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 231;

(y) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 232, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 233;

(z) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 222, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 248, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25;

(aa) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 223, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 248, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25;

(bb) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 223, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 246, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 248, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25; or

(cc) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 223, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 247, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 248, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25.

15. The method of claim 3 , wherein:

(a) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 11, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 23, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25;

(b) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 15, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 27, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 28;

(c) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 18, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 29, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 30, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 31;

(d) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 20, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 21, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 22, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 32, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 33, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 34;

(e) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 89, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 90, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 91, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 92, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 93, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 94;

(f) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 95, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 96, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 97, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 98, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 99, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 100;

(g) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 101, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 102, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 103, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 104, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 105, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 106;

(h) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 107, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 108, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 109, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 110, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 111, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 112;

(i) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 113, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 114, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 115, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 116, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 117, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 118;

(j) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 119, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 120, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 121, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 122, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 123, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 124;

(k) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 125, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 126, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 127, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 128, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 129, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 130;

(l) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 131, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 132, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 133, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 134, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 135, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 136;

(m) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 137, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 138, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 139, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 140, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 141, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 142;

(n) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 143, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 144, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 145, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 146, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 147, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 148;

(o) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 149, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 150, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 151, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 152, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 153, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 154;

(p) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 18, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 208, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 209, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 31;

(q) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 252, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 208, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 213, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 31;

(r) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 253, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 208, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 213, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 31;

(s) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 218, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 219, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 224, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 28;

(t) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 225, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 226, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 227;

(u) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 225, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 228, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 227;

(v) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 229, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 227;

(w) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 228, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 227;

(x) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 230, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 231;

(y) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 232, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 233;

(z) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 222, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 248, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25;

(aa) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 223, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 248, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25;

(bb) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 223, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 246, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 248, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25; or

(cc) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 223, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 247, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 248, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25.

16. The method of claim 4 , wherein:

(a) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 11, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 23, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25;

(b) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 15, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 27, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 28;

(c) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 18, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 29, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 30, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 31;

(d) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 20, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 21, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 22, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 32, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 33, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 34;

(e) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 89, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 90, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 91, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 92, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 93, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 94;

(f) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 95, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 96, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 97, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 98, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 99, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 100;

(g) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 101, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 102, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 103, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 104, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 105, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 106;

(h) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 107, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 108, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 109, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 110, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 111, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 112;

(i) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 113, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 114, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 115, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 116, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 117, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 118;

(j) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 119, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 120, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 121, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 122, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 123, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 124;

(k) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 125, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 126, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 127, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 128, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 129, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 130;

(l) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 131, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 132, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 133, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 134, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 135, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 136;

(m) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 137, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 138, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 139, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 140, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 141, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 142;

(n) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 143, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 144, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 145, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 146, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 147, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 148;

(o) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 149, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 150, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 151, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 152, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 153, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 154;

(p) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 18, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 208, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 209, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 31;

(q) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 252, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 208, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 213, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 31;

(r) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 253, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 19, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 208, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 213, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 31;

(s) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 218, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 219, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 224, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 28;

(t) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 225, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 226, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 227;

(u) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 225, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 228, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 227;

(v) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 229, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 227;

(w) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 228, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 227;

(x) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 230, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 231;

(y) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 220, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 221, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 26, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 232, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 233;

(z) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 222, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 248, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25;

(aa) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 223, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 248, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25;

(bb) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 223, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 246, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 248, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25; or

(cc) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 223, the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 247, the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 248, the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, and the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25.

17. The method of claim 1 , wherein the anti-FAM19A5 antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein:

(i) the VH comprises the amino acid sequence set forth in SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEO ID NO: 158, SEO ID NO: 159, SEO ID NO: 160, SEO ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 211, SEQ ID NO: 214, SEQ ID NO: 249, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 250, or SEO ID NO: 251; and

(ii) the VL comprises the amino acid sequence set forth in SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 212, SEQ ID NO: 215, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, or SEQ ID NO: 245.

18. The method of claim 3 , wherein the anti-FAM19A5 antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein:

(i) the VH comprises the amino acid sequence set forth in SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEO ID NO: 158, SEO ID NO: 159, SEO ID NO: 160, SEO ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 211, SEQ ID NO: 214, SEQ ID NO: 249, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 250, or SEO ID NO: 251; and

(ii) the VL comprises the amino acid sequence set forth in SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 212, SEQ ID NO: 215, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, or SEQ ID NO: 245.

19. The method of claim 10 , wherein:

(a) the VH comprises the amino acid sequence set forth in SEQ ID NO: 35 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 39;

(b) the VH comprises the amino acid sequence set forth in SEQ ID NO: 36 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 40;

(c) the VH comprises the amino acid sequence set forth in SEQ ID NO: 37 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 41;

(d) the VH comprises the amino acid sequence set forth in SEQ ID NO: 38 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 42;

(e) the VH comprises the amino acid sequence set forth in SEQ ID NO: 155 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 166;

(f) the VH comprises the amino acid sequence set forth in SEQ ID NO: 156 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 167;

(g) the VH comprises the amino acid sequence set forth in SEQ ID NO: 157 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 168;

(h) the VH comprises the amino acid sequence set forth in SEQ ID NO: 158 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 169;

(i) the VH comprises the amino acid sequence set forth in SEQ ID NO: 159 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 170;

(j) the VH comprises the amino acid sequence set forth in SEQ ID NO: 160 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 171;

(k) the VH comprises the amino acid sequence set forth in SEQ ID NO: 161 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 172;

(l) the VH comprises the amino acid sequence set forth in SEQ ID NO: 162 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 173;

(m) the VH comprises the amino acid sequence set forth in SEQ ID NO: 163 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 174;

(n) the VH comprises the amino acid sequence set forth in SEQ ID NO: 164 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 175;

(o) the VH comprises the amino acid sequence set forth in SEQ ID NO: 165 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 176;

(p) the VH comprises the amino acid sequence set forth in SEQ ID NO: 211 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 212;

(q) the VH comprises the amino acid sequence set forth in SEQ ID NO: 214 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 215;

(r) the VH comprises the amino acid sequence set forth in SEQ ID NO: 249 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 215;

(s) the VH comprises the amino acid sequence set forth in SEQ ID NO: 234 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 238;

(t) the VH comprises the amino acid sequence set forth in SEQ ID NO: 235 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 239;

(u) the VH comprises the amino acid sequence set forth in SEQ ID NO: 235 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 240;

(v) the VH comprises the amino acid sequence set forth in SEQ ID NO: 235 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 241;

(w) the VH comprises the amino acid sequence set forth in SEQ ID NO: 235 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 242;

(x) the VH comprises the amino acid sequence set forth in SEQ ID NO: 235 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 243;

(y) the VH comprises the amino acid sequence set forth in SEQ ID NO: 235 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 244;

(z) the VH comprises the amino acid sequence set forth in SEQ ID NO: 236 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 245;

(aa) the VH comprises the amino acid sequence set forth in SEQ ID NO: 250 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 245;

(bb) the VH comprises the amino acid sequence set forth in SEQ ID NO: 237 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 245; or

(cc) the VH comprises the amino acid sequence set forth in SEQ ID NO: 251 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 245.

20. The method of claim 17 , wherein:

(a) the VH comprises the amino acid sequence set forth in SEQ ID NO: 35 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 39;

(b) the VH comprises the amino acid sequence set forth in SEQ ID NO: 36 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 40;

(c) the VH comprises the amino acid sequence set forth in SEQ ID NO: 37 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 41;

(d) the VH comprises the amino acid sequence set forth in SEQ ID NO: 38 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 42;

(e) the VH comprises the amino acid sequence set forth in SEQ ID NO: 155 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 166;

(f) the VH comprises the amino acid sequence set forth in SEQ ID NO: 156 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 167;

(g) the VH comprises the amino acid sequence set forth in SEQ ID NO: 157 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 168;

(h) the VH comprises the amino acid sequence set forth in SEQ ID NO: 158 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 169;

(i) the VH comprises the amino acid sequence set forth in SEQ ID NO: 159 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 170;

(j) the VH comprises the amino acid sequence set forth in SEQ ID NO: 160 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 171;

(k) the VH comprises the amino acid sequence set forth in SEQ ID NO: 161 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 172;

(l) the VH comprises the amino acid sequence set forth in SEQ ID NO: 162 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 173;

(m) the VH comprises the amino acid sequence set forth in SEQ ID NO: 163 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 174;

(n) the VH comprises the amino acid sequence set forth in SEQ ID NO: 164 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 175;

(o) the VH comprises the amino acid sequence set forth in SEQ ID NO: 165 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 176;

(p) the VH comprises the amino acid sequence set forth in SEQ ID NO: 211 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 212;

(q) the VH comprises the amino acid sequence set forth in SEQ ID NO: 214 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 215;

(r) the VH comprises the amino acid sequence set forth in SEQ ID NO: 249 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 215;

(s) the VH comprises the amino acid sequence set forth in SEQ ID NO: 234 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 238;

(t) the VH comprises the amino acid sequence set forth in SEQ ID NO: 235 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 239;

(u) the VH comprises the amino acid sequence set forth in SEQ ID NO: 235 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 240;

(v) the VH comprises the amino acid sequence set forth in SEQ ID NO: 235 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 241;

(w) the VH comprises the amino acid sequence set forth in SEQ ID NO: 235 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 242;

(x) the VH comprises the amino acid sequence set forth in SEQ ID NO: 235 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 243;

(y) the VH comprises the amino acid sequence set forth in SEQ ID NO: 235 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 244;

(z) the VH comprises the amino acid sequence set forth in SEQ ID NO: 236 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 245;

(aa) the VH comprises the amino acid sequence set forth in SEQ ID NO: 250 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 245;

(bb) the VH comprises the amino acid sequence set forth in SEQ ID NO: 237 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 245; or

(cc) the VH comprises the amino acid sequence set forth in SEQ ID NO: 251 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 245.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2024
From: KIM, BONGCHEOL; KIM, DONG SIK; LEE, JAE-KEUN; SHIM, JUWON
To: NEURACLE SCIENCE CO., LTD.
Reel/Frame 069553/0255 →
Continuity (2)
Provisional Application 62785569 · Dec 27, 2018
Related Publication 20220064277A1 · Mar 3, 2022
References Cited (103)
US 4044126A · Cook et al. · 1977 [cited by applicant]
US 4364923A · Cook et al. · 1982 [cited by applicant]
US 4414209A · Cook et al. · 1983 [cited by applicant]
US 5693780A · Newman et al. · 1997 [cited by applicant]
US 5709874A · Hanson et al. · 1998 [cited by applicant]
US 5759542A · Gurewich · 1998 [cited by applicant]
US 5840674A · Yatvin et al. · 1998 [cited by applicant]
US 5860957A · Jacobsen et al. · 1999 [cited by applicant]
US 5900252A · Calanchi et al. · 1999 [cited by applicant]
US 5948433A · Burton et al. · 1999 [cited by applicant]
US 5972366A · Haynes et al. · 1999 [cited by applicant]
US 5983134A · Ostrow · 1999 [cited by applicant]
US 5985307A · Hanson et al. · 1999 [cited by applicant]
US 5985317A · Venkateshwaran et al. · 1999 [cited by applicant]
US 6004534A · Langer et al. · 1999 [cited by applicant]
US 6010715A · Wick et al. · 2000 [cited by applicant]
US 6024975A · D'Angelo et al. · 2000 [cited by applicant]
US 6039975A · Shah et al. · 2000 [cited by applicant]
US 6048736A · Kosak · 2000 [cited by applicant]
US 6060082A · Chen et al. · 2000 [cited by applicant]
US 6071495A · Unger et al. · 2000 [cited by applicant]
US 6120751A · Unger · 2000 [cited by applicant]
US 6131570A · Schuster et al. · 2000 [cited by applicant]
US 6139865A · Friend et al. · 2000 [cited by applicant]
US 6167301A · Flower et al. · 2000 [cited by applicant]
US 6253872B1 · Neumann · 2001 [cited by applicant]
US 6256533B1 · Yuzhakov et al. · 2001 [cited by applicant]
US 6261595B1 · Stanley et al. · 2001 [cited by applicant]
US 6267983B1 · Fujii et al. · 2001 [cited by applicant]
US 6271359B1 · Norris et al. · 2001 [cited by applicant]
US 6274552B1 · Tamarkin et al. · 2001 [cited by applicant]
US 6316652B1 · Steliou · 2001 [cited by applicant]
US 9579398B2 · Seong et al. · 2017 [cited by applicant]
US 10640557B2 · Seong et al. · 2020 [cited by applicant]
US 11155613B2 · Kim · 2021 [cited by examiner]
US 11332521B2 · Kim · 2022 [cited by examiner]
US 11560425B2 · Kim · 2023 [cited by examiner]
US 11618783B2 · Kim · 2023 [cited by examiner]
US 11634484B2 · Kim · 2023 [cited by examiner]
US 11739141B2 · Seong et al. · 2023 [cited by applicant]
US 11746149B2 · Kim · 2023 [cited by examiner]
US 11970532B2 · Kim et al. · 2024 [cited by applicant]
US 20040014194A1 · Beyer et al. · 2004 [cited by applicant]
US 20120100140A1 · Reyes et al. · 2012 [cited by applicant]
US 20140051591A1 · O'Donnell et al. · 2014 [cited by applicant]
US 20200300870A1 · Seong et al. · 2020 [cited by applicant]
US 20210347872A1 · Kim et al. · 2021 [cited by applicant]
US 20220064277A1 · Kim et al. · 2022 [cited by applicant]
US 20220073601A1 · Kim et al. · 2022 [cited by applicant]
US 20230287096A1 · Kim et al. · 2023 [cited by applicant]
US 20230348584A1 · Kim et al. · 2023 [cited by applicant]
WO WO9712622A1 · 1997 [cited by applicant]
WO WO9817815A1 · 1998 [cited by applicant]
WO WO9817816A1 · 1998 [cited by applicant]
WO WO9818934A1 · 1998 [cited by applicant]
WO WO9931251A1 · 1999 [cited by applicant]
WO WO2017123556A1 · 2017 [cited by applicant]
WO WO2017216559A1 · 2017 [cited by applicant]
WO WO2018083538A1 · 2018 [cited by applicant]
WO WO2020136603A1 · 2020 [cited by applicant]
Wang et al., Novel adipokine, FAM19A5, inhibits neointima formation after injury through sphingosine-1-phosphate receptor 2; 2018 , Circulation, 138:48-63. (Year: 2018). [cited by examiner]
Lee et al., Design and prediction of aptamers assisted by in silico methods; 2023, Biomedicines, 11, 356. (Year: 2023). [cited by examiner]
An, Z., et al., “IgG2m4, an Engineered Antibody Isotype with Reduced Fc Function,” Mabs 1(6):572-579, Taylor & Francis, United States (Nov.-Dec. 2009). [cited by applicant]
Bergheanu, S.C., et al., “Pathophysiology and Treatment of Atherosclerosis : Current View and Future Perspective on Lipoprotein Modification Treatment,” Netherlands Heart Journal 25(4):231-242, Bohn Stafleu Van Loghum, … [cited by applicant]
Bird, R.E., et al., “Single-chain Antigen-binding Proteins,” Science 242(4877):423-426, Association for the Advancement of Science, United States (Oct. 1988). [cited by applicant]
Bricogne, G., “[23] Bayesian Statistical Viewpoint on Structure Determination: Basic Concepts and Examples,” Methods in Enzymology 276:361-423, Academic Press, United States (1997). [cited by applicant]
Bricogne, G., “Direct Phase Determination by Entropy Maximization and Likelihood Ranking: Status Report and Perspectives,” Acta Crystallographica. Section D, Biological Crystallography 49(Pt1):37-60, Wiley-Blackwell, Un… [cited by applicant]
Champe, M., et al., “Monoclonal Antibodies that Block the Activity of Leukocyte Function—Associated Antigen 1 Recognize Three Discrete Epitopes in the Inserted Domain of CD11a,” The Journal of Biological Chemistry 270 (… [cited by applicant]
Chayen, N.E., “The Role of Oil in Macromolecular Crystallization,” Structure 5(10):1269-1274, Cell Press, United States (Oct. 1997). [cited by applicant]
Cheung, R.C., et al., “Epitope-specific Antibody Response to the Surface Antigen of Duck Hepatitis B Virus in Infected Ducks,” Virology 176(2):546-552, Academic Press, United States (1990). [cited by applicant]
Chothia, C. and Lesk, A.M., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” Journal of Molecular Biology 196(4):901-917, Elsevier, Netherlands (Aug. 1987). [cited by applicant]
Cunningham, B.C. and Wells, J.A., “High-resolution Epitope Mapping of hGH-receptor Interactions by Alanine-scanning Mutagenesis,” Science 244(4908):1081-1085, American Association for the Advancement of Science, United … [cited by applicant]
Edelman, G.M., et al., “The Covalent Structure of an Entire gammaG Immunoglobulin Molecule,” Proceedings of the National Academy of Sciences USA 63(1):78-85, National Academy of Sciences, United States (May 1969). [cited by applicant]
Giege, R., et al., “Crystallogenesis of biological macromolecules: facts and perspectives,” Acta Crystallographica. Section D, Biological Crystallography 50(Pt4):339-350, Wiley-Blackwell, United States (Jul. 1994). [cited by applicant]
Harlow, E., et al., “Epitope mapping by competition assay,” CSH Protoc 2006(2):pdb.prot4277, Cold Spring Harbor Laboratory Press, United States (2006). [cited by applicant]
Harmsen, M.M. and De Haard, H.J., “Properties, Production, and Applications of Camelid Single-Domain Antibody Fragments,” Applied Microbiology and Biotechnology 77(1):13-22, Springer International, Germany (Nov. 2007). [cited by applicant]
Herrington, W., et al., “Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease,” Circulation Research 118(4):535-546, Lippincott Williams & Wilkins, United States (Feb… [cited by applicant]
Huston, U.S., et al., “Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-digoxin Single-chain Fv Analogue Produced in Escherichia Coli,” Proceedings of the National Academy of Scien… [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2019/061377, ISA/KR, Republic of Korea, mailed on Apr. 23, 2020, 9 pages. [cited by applicant]
Jefferis, R. and Lefranc, M.P., “Human Immunoglobulin Allotypes: Possible Implications for Immunogenicity,” Mabs 1(4):332-338, Taylor & Francis, United States (Jul.-Aug. 2009). [cited by applicant]
Kabat, E.A. and Wu, T.T., “Attempts to Locate Complementarity-Determining Residues in the Variable Positions of Light and Heavy Chains,” Annals of the New York Academy of Sciences 190:382-393, Blackwell, United States (… [cited by applicant]
Kabat, E.A., et al., “Sequences of proteins of immunological interest,” 5th Edition, NIH publication No. 91-3242, U.S. Department of Public Health and Human Services, National Institutes of Health, United States (1991). [cited by applicant]
Kirkland, T.N., et al., “Analysis of the Fine Specificity and Cross-reactivity of Monoclonal Anti-lipid A Antibodies,” Journal of Microbiology 137(11):3614-3619, Microbiological Society of Korea, Korea (1986). [cited by applicant]
Kostelny, S.A., et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” The Journal of Immunology 148(5):1547-1553, American Association of Immunologists, United States (Mar. 1992). [cited by applicant]
Lau, C., et al., “Chimeric Anti-CD14 IGG2/4 Hybrid Antibodies for Therapeutic Intervention in Pig and Human Models of Inflammation,” Journal of Immunology 191(9):4769-4777, American Association of Immunologists, United … [cited by applicant]
Lefranc, M.P., et al., “IMGT Unique Numbering for Immunoglobulin and T Cell Receptor Variable Domains and Ig Superfamily V-like Domains,” Developmental and Comparative Immunology 27(1):55-77, Elsevier Science, United St… [cited by applicant]
Lonberg, N., et al., “Human Antibodies from Transgenic Animals,” Nature Biotechnology 23(9):1117-1125, Nature Publishing Company, United States (Sep. 2005). [cited by applicant]
Lu, H. and Daugherty, A., “Recent Highlights of ATVB Atherosclerosis, ” Arteriosclerosis, Thrombosis, and Vascular Biology 35(3):485-491, Lippincott Williams & Wilkins, United States (Mar. 2015). [cited by applicant]
McCafferty, J., et al., “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains,” Nature 348(6301):552-554, Nature Publishing Group, London (Dec. 1990). [cited by applicant]
McPherson, A., “Crystallization of Proteins From Polyethylene Glycol,” The Journal of Biological Chemistry 251(20):6300-6303, Elsevier Inc. on behalf of American Society for Biochemistry and Molecular Biology, United St… [cited by applicant]
McPherson, A., “Current Approaches to Macromolecular Crystallization,” European Journal of Biochemistry 189(1):1-23, Blackwell Science Ltd, England (Apr. 1990). [cited by applicant]
Moldenhauer, G., et al., “Identity of HML-1 Antigen on Intestinal Intraepithelial T Cells and of B-ly7 Antigen on Hairy Cell Leukaemia,” Scandinavian Journal of Immunology 32(2):77-82, Blackwell Scientific Publications,… [cited by applicant]
Morel, G.A., et al., “Monoclonal Antibodies to Bovine Serum Albumin: Affinity and Specificity Determinations,” Molecular Immunology 25(1):7-15, Pergamon Press, England (1988). [cited by applicant]
Morris, G.E., “Epitope Mapping by Chemical Fragmentation,” Methods in Molecular Biology 66:121-127, Humana Press, United States (1996). [cited by applicant]
Roux, K.H., et al., “Comparisons of the Ability of Human IgG3 Hinge Mutants, IgM, IgE, and IgA2, to form Small Immune Complexes: A Role for Flexibility and Geometry,” The Journal of Immunology 161(8):4083-4090, American… [cited by applicant]
Roversi, P., et al., “Modelling Prior Distributions of Atoms for Macromolecular Refinement and Completion,” Acta Crystallographica. Section D, Biological Crystallography 56(Pt10):1316-1323, Wiley-Blackwell, United State… [cited by applicant]
Songsivilai, S. and Lachmann, P.J., “Bispecific Antibody: A Tool for Diagnosis and Treatment of Disease,” Clinical and Experimental Immunology 79(3):315-321, Blackwell Scientific Publications, England (1990). [cited by applicant]
Stahli, C., et al., “Distinction of Epitopes by Monoclonal Antibodies,” Methods in Enzymology 92:242-253, Academic Press, United States (1983). [cited by applicant]
Stroes, E.S., et al., “Statin-associated Muscle Symptoms: Impact on Statin Therapy-european Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management,” European Heart Journal 36(17):1012-… [cited by applicant]
Tang, Y.T., et al., “TAFA: A Novel Secreted Family With Conserved Cysteine Residues and Restricted Expression in the Brain,” Genomics 83(4):727-734, Academic Press, United States (Apr. 2004). [cited by applicant]
Vidarsson, G., et al., “IgG Subclasses and Allotypes: From Structure to Effector Functions,” Frontiers in Immunology 5:520, Frontiers Research Foundation, Switzerland (Oct. 2014). [cited by applicant]
Wang, Y., et al., “Novel Adipokine, FAM19A5, Inhibits Neointima Formation After Injury Through Sphingosine-1-phosphate Receptor 2,” Circulation, 138(1):48-63, Lippincott Williams & Wilkins, United States (Jul. 2018). [cited by applicant]
Ward, E.S., et al., “Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from [cited by applicant]